ACADIA Pharmaceuticals CFO Sells $836,100 in Stock (ACAD)
ACADIA Pharmaceuticals (NASDAQ:ACAD) CFO Thomas Aasen unloaded 30,000 shares of ACADIA Pharmaceuticals stock on the open market in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $27.87, for a total value of $836,100.00. Following the sale, the chief financial officer now directly owns 24,085 shares of the company’s stock, valued at approximately $671,249. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.
Several analysts have recently commented on the stock. Analysts at Roth Capital raised their price target on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from $20.00 to $23.00 in a research note to investors on Thursday, August 8th. They now have a “buy” rating on the stock. Separately, analysts at Zacks reiterated an “outperform” rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) in a research note to investors on Wednesday, August 7th. They now have a $26.00 price target on the stock. Finally, analysts at Ladenburg Thalmann raised their price target on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from $15.00 to $24.00 in a research note to investors on Wednesday, August 7th. They now have a “buy” rating on the stock. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $23.43.
Shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) traded up 1.88% on Friday, hitting $28.77. The stock had a trading volume of 1,866,124 shares. ACADIA Pharmaceuticals has a one year low of $1.80 and a one year high of $29.73. The stock has a 50-day moving average of $23.11 and a 200-day moving average of $17.10. The company’s market cap is $2.554 billion.
ACADIA Pharmaceuticals (NASDAQ:ACAD) last released its earnings data on Tuesday, August 6th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by $0.02. The company had revenue of $451.00 million for the quarter, compared to the consensus estimate of $0.45 million. Analysts expect that ACADIA Pharmaceuticals will post $-0.44 EPS for the current fiscal year.
ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.